There are currently 554 clinical trials in Madison, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Wisconsin, University of Wisconsin Hospital and Clinics, University of Wisconsin-Madison and University of Wisconsin Carbone Cancer Center - University Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021
Recruiting
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients must also be positive for HLA-A\*11:01. The purpose of this study is to find the best dose of AFNT-211 t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Register for Updates
Well-being Training for Adolescent Depressive Symptoms (TeenWell Study)
NCT06626425
Recruiting
This study is being done to see if the Healthy Minds Program app helps adolescents with elevated depressive symptoms. Up to 200 participants will be on study for 20 weeks.
Gender:
ALL
Ages:
Between 14 years and 19 years
Trial Updated:
02/24/2025
Locations: Center for Healthy Minds, University of Wisconsin Madison, Madison, Wisconsin
Conditions: Depression
Register for Updates
Speech Pattern Evaluation and Analysis for Knowledge of AD
NCT06230783
Recruiting
The goal of this observational study is to validate changes in speech as a measure of cognition in individuals at increased risk of Alzheimer's disease and related dementias (ADRD). This study aims to clarify how speech may be affected by Alzheimer's disease. Participants will complete speech collection sessions and a survey at home using an iPad. Participants can expect to be in the study for 3 years.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
02/21/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Wisconsin Alzheimer's Disease Research Center, Wisconsin Registry for Alzheimer's Prevention
Register for Updates
Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT04886531
Recruiting
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of week 4 of treatment. Following surgery, patients will receive standard of care HER2-directed and endocrine therapy at the treating physician's discretion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Register for Updates
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
NCT04088071
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
NCT05844982
Recruiting
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: The Board of Regents of the University of Wisconsin System, Madison, Wisconsin
Conditions: Radiation Retinopathy, Visual Impairment
Register for Updates
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
NCT05904028
Recruiting
Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/18/2025
Locations: The Board of Regents of the University of Wisconsin System, Madison, Wisconsin
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage
NCT06342375
Recruiting
The goal of this study is to try new outreach methods to improve access to Medicaid for those who lost Medicaid for procedural reasons. The main questions it aims to answer are: 1. How does a live phone call from a Navigator impact Medicaid enrollment among people who lost Medicaid coverage for procedural reasons? 2. What is the effectiveness of outreach using a live call rather than a pre-recorded call?
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/18/2025
Locations: University of Wisconsin - Madison, Madison, Wisconsin
Conditions: No Medicaid Coverage
Register for Updates
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
NCT05585320
Recruiting
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: University of Wisconsin Clinical Science Center, Madison, Wisconsin
Conditions: Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor
Register for Updates
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
NCT06601686
Recruiting
The goal of this clinical trial is to learn whether brain stimulation technology can help people reach a meditative state quickly and easily without years of meditation training. The researchers want to see if this will help people distance themselves from their thoughts and feeling, and if this will lead to improvements in openness and wellbeing the same way meditation can. Participants will: * Complete questionnaires * Perform a guided meditation task (The Bell Task) * Wear a high density el... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/18/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Healthy
Register for Updates
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605
Recruiting
Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants
NCT06776679
Recruiting
The purpose of this study is to determine the absorption, metabolism, and excretion of \[14C\]-BGB-16673 and to characterize and determine, where possible, the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
02/17/2025
Locations: Fortrea Clinical Research Unit Inc, Madison, Wisconsin
Conditions: Healthy Volunteers
Register for Updates